INTUITIVE SURGICAL INC 8K
0001035267-26-000047
View on SEC EDGARIntuitive Surgical, Inc. announced strong second-quarter 2026 results with double-digit revenue and earnings growth, expanded robotic system placements, tariff-related income benefits, share repurchases, and reiterated full-year 2026 guidance for procedure growth and margins.
On July 16, 2026, Intuitive (Intuitive Surgical, Inc.) reported its financial results for the quarter ended June 30, 2026, highlighting 16% worldwide procedure growth across its da Vinci and Ion platforms, a 19% year-over-year revenue increase to $2.89 billion, and GAAP net income of $818 million ($2.29 per diluted share) and non-GAAP net income of $1.00 billion ($2.80 per diluted share). The company expanded its installed base to 11,710 da Vinci systems and 1,096 Ion systems, placed 468 da Vinci systems (including 246 da Vinci 5 systems) and 55 Ion systems, and noted a $28 million net benefit from tariff refunds under the International Emergency Economic Powers Act. Management also repurchased 0.9 million shares for $0.38 billion, ended the quarter with $8.63 billion in cash and investments, and provided 2026 guidance calling for worldwide da Vinci procedure growth of approximately 13.5%–15.5%, non-GAAP gross margin of 68%–69% (including a 1% tariff impact), and non-GAAP operating expense growth of 11%–13%, while cautioning that additional tariffs could materially affect results.
Filing Facts
- CIK
- 1035267
- Ticker
- ISRG
- Form
- 8K
- Source Type
- sec
- Accession
- 0001035267-26-000047
- Alert Tier
- 9